A Study to Examine Anktiva for the Treatment of Long COVID
Phase 2
40
about 11 months
18–70
1 site in CA
About this study
This trial is testing if Anktiva can help people with long-term symptoms after a COVID-19 infection. The treatment will last 330 days and involve taking Anktiva medication.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Anktiva
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Clinically important changes in vital signs such as blood pressure in millimeters of mercury (mmHg)., Clinically important changes in vital signs such as heart rate in beats per minute., Incidence of grade 3 or higher TEAEs through 30 days post final study drug administration., Incidence of serious adverse events (SAEs) through 30 days post final study drug administration., Incidence of treatment emergent adverse events (TEAEs) through 30 days post final study drug administration.
Infectious